ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Using Basiliximab Does Not Increase De Novo DSA Incidence but Reduces Cytomegalovirus Infections and Neoplastic Complications in Non-Sensitized Kidney Transplant Patients.

M. Marron-Wojewodzki,1 I. Szwarc,1 C. Rene,2 J.-F. Eliaou,2 G. Mourad,1 M. Le Quintrec.1,3

1Department of Nephrology, Dialysis and Transplantation, Hôpital Lapeyronie, Montpellier University Hospital, Montpellier, France
2Departement of Immunology, Hôpital Saint Eloi, Montpellier University Hospital, Montpellier, France
3Inserm U1183, IRMB, Hôpital Saint Eloi, Montpellier University Hospital, Montpellier, France

Meeting: 2017 American Transplant Congress

Abstract number: B190

Keywords: Alloantibodies, Antilymphocyte antibodies, Interleukin-2 receptor, Kidney transplantation

Session Information

Session Name: Poster Session B: Kidney Immunosuppression: Induction Therapy

Session Type: Poster Session

Date: Sunday, April 30, 2017

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall D1

Background. In kidney transplantation, de novo donor specific antibodies (dnDSA) are associated with antibody-mediated rejection (AMR) and graft failure. After dnDSA development, 24% of the patients will fail within 3 years. Considering the deleterious effect of dnDSA on graft outcome and the lack of effective treatment of AMR, clinicians must avoid alloimmunization. As the influence of induction therapies on dnDSA generation, in low-immunological risk kidney transplant recipients, is unknown, we analysed its impact on dnDSA incidence in a cohort of non-sensitized patients.

Methods. Patients receiving, in our centre, a first kidney transplant between January 2008 and December 2014, and an induction therapy by ATG or basiliximab were eligible for the study. We excluded combined and ABO-incompatible transplantations and patients with pre-transplantation anti-HLA immunization. Pre-transplant immunization was defined as at least one anti-HLA antibody with mean fluorescence intensity superior at 500. Early graft failures, defined by primary graft dysfunction and vascular thrombosis arising during the first week after transplantation, have also been excluded.

Results. 303 kidney transplant recipients were included. Recipient age was 52.2 ± 14 years. 84 (27.7%) patients were treated with basiliximab and 219 (72.3%) patients with ATG with a mean dose of 375.75 ± 104 mg. Baseline demographics and characteristics were similar between the two groups. During the follow-up period (5.1 [3.0; 7.3] years), 44 (14.5%) patients developed dnDSA, 35 (16.0%) in the ATG group and 9 (10.7%) in the basiliximab group (Log-rank C2=0.32, p=0.57). Graft survival was 86% in the ATG group and 81% in the basiliximab group (p=0.38). There were significantly more cytomegalovirus infection (52% versus 33%, p=0,01) and neoplastic diseases (17% versus 7%, p=0,03) in the ATG group.

Conclusions. In patients with low immunological risk, induction with basiliximab is associated with a reduction of infectious and neoplastic complications occurrence compared to ATG induction, without increasing dnDSA development.

CITATION INFORMATION: Marron-Wojewodzki M, Szwarc I, Rene C, Eliaou J.-F, Mourad G, Le Quintrec M. Using Basiliximab Does Not Increase De Novo DSA Incidence but Reduces Cytomegalovirus Infections and Neoplastic Complications in Non-Sensitized Kidney Transplant Patients. Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Marron-Wojewodzki M, Szwarc I, Rene C, Eliaou J-F, Mourad G, Quintrec MLe. Using Basiliximab Does Not Increase De Novo DSA Incidence but Reduces Cytomegalovirus Infections and Neoplastic Complications in Non-Sensitized Kidney Transplant Patients. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/using-basiliximab-does-not-increase-de-novo-dsa-incidence-but-reduces-cytomegalovirus-infections-and-neoplastic-complications-in-non-sensitized-kidney-transplant-patients/. Accessed May 9, 2025.

« Back to 2017 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences